APMD · XBRL financial data
Apnimed financial statements, every quarter
The same tables from 1 filing, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters
| In thousands of dollars | Jun 30, 2026 |
|---|---|
| Revenue | 12,080 |
| Research and development | 9,900 |
| General and administrative | 12,674 |
| Total operating expenses | 23,784 |
| Operating income (loss) | (11,704) |
| Other income (expense) | (2,738) |
| Income tax expense (benefit) | 0 |
| Net income (loss) | 125,935 |
| Weighted average shares, basic thousands of shares | 4,797 |
| Weighted average shares, diluted thousands of shares | 32,353 |
Balance sheet
CSVFiscal quarters
| In thousands of dollars | Jun 30, 2026 |
|---|---|
| Cash and cash equivalents | 172,804 |
| Accounts receivable | 690 |
| Prepaid and other current assets | 5,092 |
| Total current assets | 184,772 |
| Property and equipment, net | 53 |
| Right-of-use asset | 714 |
| Total assets | 195,456 |
| Accounts payable | 6,598 |
| Total current liabilities | 35,578 |
| Long-term debt | 40,267 |
| Lease liability, non-current | 485 |
| Total liabilities | 125,698 |
| Accumulated deficit | (203,690) |
| Total stockholders' equity | (176,181) |
| Total liabilities and equity | 195,456 |
| Common shares outstanding (cover page) thousands of shares | 41,631 |
Cash flows
CSVFiscal quarters
| In thousands of dollars | Jun 30, 2026 |
|---|---|
| Net income (loss) | 125,935 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Apnimed | 172,804 | 12,080 | not reported | 41.6M | — | 10-QJun 30, 2026 |
| Merus | 367,491 | 12,150 | (84,917)* | 75.8M | 9.6 quarters | 10-QSep 30, 2025 |
| Editas Medicine | 181,815 | 11,890 | (29,568)* | 153.6M | 7.2 quarters | 10-QJun 30, 2026 |
| XOMA Royalty | 85,600 | 12,318 | 6,121 | 12.5M | — | 10-QMar 31, 2026 |
| Abeona Therapeutics | 56,229 | 11,380 | (17,496)* | 57.2M | 8.4 quarters | 10-QJun 30, 2026 |
| Stoke Therapeutics | 107,271 | 11,255 | (62,686)* | 65.4M | 5.2 quarters | 10-QSep 30, 2026 |
| Lexicon Pharmaceuticals | 44,081 | 11,250 | (8,079)* | 445.2M | 17.2 quarters | 10-QSep 30, 2026 |
| Wave Life Sciences | 197,315 | 13,158 | (60,142)* | 197.2M | 7.4 quarters | 10-QSep 30, 2026 |
| Mersana Therapeutics | 56,391 | 11,009 | (3,192)* | 5.0M | 17.7 quarters | 10-QSep 30, 2025 |
Not investment advice. Not affiliated with the U.S. SEC.